IV NAD+: the biology is real, the wellness evidence is missing

Edited by Samael A. Tejada, Founder & Editor-in-Chief

A new narrative review in Frontiers in Aging (September 26, 2026) on intravenous NAD+ and NAD+ precursors in wellness and translational medicine does something unusual for this literature: it makes the mitochondrial case honestly, then states the evidence gap plainly. The biology is clear — support for electron-transport-chain efficiency, SIRT1/PGC-1α-driven mitochondrial biogenesis, and improved glutathione balance via Nrf2-dependent biosynthesis. But the review concludes that clinical effectiveness for wellness and healthy aging remains inconclusive, and notes that no eligible clinical-outcomes trials evaluating IV NAD+ itself for anti-aging or wellness indications exist (per a 2026 systematic review).

What does the review actually establish?

The mechanistic picture: NAD+ sits at the center of mitochondrial energy production, and its precursors can activate the SIRT1/PGC-1α biogenesis axis and bolster antioxidant defenses. In cells and animals, that biology is well-documented.

What is missing?

Two things. First, human studies have not established whether intact IV NAD+ actually distributes to tissues — the drug may not reach the places the marketing says it works. Second, there are no clinical-outcome trials of IV NAD+ itself for the wellness and anti-aging indications clinics are selling. Mechanism without outcomes is a hypothesis, not a treatment.

How does this sit next to the new Cambridge NR trial?

Contrast is the point: the Cambridge trial (oral NR, mitochondrial DNA disease, biopsy-confirmed tissue effects in a defined patient group) is what an evidence base starts to look like. IV NAD+ for general wellness has the same plausible biology but none of the human tissue or outcome data — yet it is sold far more broadly.

What should a consumer ask before booking a drip?

Ask what outcome the drip has actually been tested against, in whom, and with what tissue-level evidence — and be wary of any clinic that cites mechanistic biology as if it were clinical proof. Plausible is not proven.

Where the evidence stands

• Established: The mitochondrial mechanisms — electron-transport support, SIRT1/PGC-1α biogenesis signaling, Nrf2-linked glutathione effects — are well-documented in cells and animal models.
• Absent: No eligible clinical-outcomes trials of IV NAD+ itself for anti-aging or wellness indications. Human tissue distribution of intact IV NAD+ is not established.
• Preliminary: Whether IV administration achieves tissue-level NAD+ effects comparable to oral precursors in any human population.